Biogen

Youtube Subscribe

Open: 249.13 Close: 251.18 Change: 2.05

What an AI found about Biogen after reading the whole Internet.

The game is changing. There is a new strategy to evaluate Biogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, price, share, stock, Inc, BIIB, Stock, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Evelo Biosciences announced it is cutting its workforce.

Today's News

Biogen Inc. (BIIB) Statistics & Valuation Metrics - Stock Analysis. Biogen has 144.90 million shares outstanding. Average price target for Biogen is $324.85. Biogen is laying off an unspecified number of employees, according to a report published Monday by the Boston Business Journal. Evelo Biosciences announced it is cutting its workforce and dropping an atopic dermatitis program in an effort to extend its cash flow. The current Biogen [ BIIB ] share price is $248.30.30. Over the next 52 weeks, Biogen has on average historically risen by 47.8%. Biogen (NASDAQ:BIIB) stock opened at $248.30 on Tuesday. Biogen has a 52 week low of $220.86 and a 52-week high of $319.76. Analysts expect Biogen to post 14.96 earnings per share for the current fiscal year. Biogen exhibits a price/sales ratio which is less than the industry average for drugs stocks listed on the NASDAQ. At this time, I would like to welcome everyone to the Biogen third quarte... Is Biogen Stock a Buy Now? September 28th, 2023. Biogen, Sage set price of postpartum depression pill at $15,900. Biogen Inc. stock underperforms monday when compared to competitors - marketwatch.com. Share price of Biogen pharmachem industries share price ₹1.46 today: market cap, price chart, financials and fundamental analysis worth seeing! Check why we had a strong conviction.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Biogen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, price, share, stock, Inc, BIIB, Stock, and the most common words in the summary are: biogen, market, drug, stock, tysabri, factor, human, . One of the sentences in the summary was: Evelo Biosciences announced it is cutting its workforce.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #market #drug #stock #tysabri #factor #human.

Read more →

Youtube Subscribe

---